Services & Contact
Dr A. Domdey
Team Coordinator
Thinking beyond GLP‑1
Dear colleagues,
Knowledge about GLP‑1, obesity, and treatment options is growing constantly. Here you can request new information and working materials on this wide‑ranging and fascinating topic on a regular basis.
Tip: If you prefer to make it easy, we can automatically inform you whenever there is something new — up to four times per year — via your practice email address or by fax.
Yes, please send me new knowledge about thinking beyond GLP‑1!
Events
Certmedica will be present in 2026 with formoline L112 at selected national and international specialist congresses. On site, we will present up‑to‑date information and be available for one-to-one professional exchange with medical experts.
12–15 May 2026ECO 33rd European Congress of Obesity
22–25 June 2026BIO International Convention
15–17 October 2026DGA Industry Forum for Angiology and Vascular Surgery
21–24 October 202666th Congress of the German Society for Gynaecology and Obstetrics (DGGG)
8–10 July 2026CPhI South East Asia
13–14 November 2026Diabetes Autumn Meeting 2026
Publications and services
Rondanelli, M. et al. (2025)
Subgroup analysis on the effect of polyglucosamine on parameters of the metabolic syndrome (Rondanelli et al. 2025)
formoline L112 EXTRA led to a significant reduction in body weight, BMI and body fat. After only three months, 50% of the patients were considered recovered.
A case collection by Grebe, W. et al. (2024).
Long‑term observation on weight control with polyglucosamine L112, available in two strengths depending on individual needs (Grebe et al. 2024).
In an observation of 25 female patients, 21 maintained their reduced weight largely stably over a period of 10 years while using polyglucosamine L112. This indicates that polyglucosamine L112 supports long‑term weight control with good tolerability.
Rondanelli, M. et al. (2023)
In an observation of 25 female patients, 21 maintained their reduced weight largely stably over a period of 10 years while using polyglucosamine L112. This indicates that polyglucosamine L112 supports long‑term weight control with good tolerability.
Taking formoline L112 increased weight loss threefold and additionally improved important health markers such as insulin levels and insulin resistance.
Perna, S., et al. (2020)
A meta‑analysis on the effect of polyglucosamine on weight loss and metabolic parameters in obesity (Perna et al. 2020).
The meta‑analysis shows that polyglucosamine, when combined with calorie reduction and physical activity, significantly reduces body weight, BMI and waist circumference. Since increased waist circumference is associated with cardiometabolic risks, its reduction may contribute to lowering those risks.
Cornelli U. et al. (2017)
A long‑term study on obesity therapy (Cornelli et al. 2017).
formoline L112 is the only weight‑loss medical device, with a 12‑month clinical long‑term study. On average, participants were able to reduce their waist circumference by more than 13 cm and lose over 12 kg.
Cnubben N. H. P. et al. (2016)
A study on lipid absorption from dietary fats with and without polyglucosamine L112 (Cnubben et al. 2016).
formoline L112 acts like a strong calorie magnet, attracting up to two‑thirds of the high‑calorie dietary fats consumed and thereby blocking their utilization in the body.
Stay Informed
Subscribe to our Practice Update for the latest clinical updates, research findings and educational opportunities.
By subscribing, you agree to receive communications from Certmedica International GmbH. You also agree to the Privacy Policy of Certmedica International GmbH. You can unsubscribe at any time.
Thank You for Your Interest!
Your request has been successfully submitted. You will shortly receive further information about Rethinking GLP‑1 as well as current content, services and practice-relevant updates.
Download file
Contact
How to reach us
"Thinking beyond GLP-1" is an initiative of Certmedica International GmbH. www.certmedica.com
Address
Certmedica International GmbH
Magnolienweg 17
63741 Aschaffenburg
Germany
FAQ
Results from a systematic review based on 9,341 patients, following an average treatment duration of 39 weeks with a GLP‑1 agonist, show an average monthly weight regain of 0.8 kg after discontinuation of therapy.1
In a systematic review based on 9,341 patients, a return of all cardiometabolic parameters to baseline values was predicted within 1.4 years.1
formoline L112 EXTRA can be used both pre‑GLP‑1 as an entry therapy for overweight and post‑GLP‑1 to help counteract the yo‑yo effect.
formoline L112 EXTRA acts purely physically and locally in the gastrointestinal tract and is not absorbed into the body.2
Results of a double‑blind, randomised study involving 100 participants with a BMI > 30 to ≤ 35 showed a weight loss of 12.1 kg after one year of therapy with the lower‑dose preparation formoline L112 in combination with lifestyle modification.3
Within one year, waist circumference can be reduced by 13.3 cm. This is a good indicator of a reduction in visceral abdominal fat.³ This has a positive effect on metabolic syndrome.
formoline L112 is taken orally twice daily as two tablets with the main meals with the highest fat content.2
formoline L112 EXTRA is very well tolerated. The product acts purely physically and is not absorbed through the intestinal wall.2
formoline L112 EXTRA can be taken long term.4
Overall, 19% of men and women in Germany are affected by obesity.5
In Germany, 27.6% of women and 41.3% of men are overweight without obesity.5
Prerequisites for pharmacological therapy for weight reduction or for maintaining achieved weight loss are:6
- ein BMI ≥ 27 kg/m2 (when using a lipase inhibitor: BMI ≥ 28) together with obesity‑associated risk factors and/or comorbidities, or
- ein BMI ≥ 30 kg/m2
Practice Updates
Stay Informed